Skip to main content
. 2018 May 18;18(2):135–147. doi: 10.3727/105221618X15174108894682

Figure 2.

Figure 2

EMD1214063 treatment of the Met-β-catenin model temporally decreases V5-tag (c-MET) but not Myc-tag (β-catenin). (A) Microscopic foci show positivity for both Myc-tag and V5-tag in the control group at both 8 and 11 weeks. EMD1214063 treatment did not have any effect on staining for Myc-tag. Staining for V5-tag showed smaller and fainter positive tumor foci after 8 weeks of EMD1214063, but no difference was observed at 11 weeks. (B) Quantification of immunohistochemistry (IHC) verified lack of significant differences in Myc-tag but showed a significant decrease in V5-tag staining (*p = 0.0465) after EMD1214063 treatment for 8 weeks only. (C) Western blot for Myc-tag showed decrease in Myc-tag levels at 8 weeks of EMD1214063 treatment only. GAPDH shows comparable loading in all lanes. (D) IHC for α-fetoprotein shows tumors to be positive in both control- and EMD1214063-treated group at both 8 and 11 weeks.